Clinical effect of hepatectomy versus extracapsular peeling in treatment of hepatic hemangioma

Chen Kai; Li XiangNong; Liu Kun; Nan YunGuang; Yang Jun

doi:10.3969/j.issn.1001-5256.2017.04.020

Issue 4

Apr. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(4): 699-704

PDF( 1481 KB)

Clinical effect of hepatectomy versus extracapsular peeling in treatment of hepatic hemangioma

DOI: 10.3969/j.issn.1001-5256.2017.04.020

Department of Hepatobiliary Surgery, The Affiliated Hospital of Xuzhou Medical University

Received Date: 2016-10-26
Published Date: 2017-04-20

Abstract

Abstract

Objective To investigate the clinical effect of hepatectomy versus extracapsular peeling in the treatment of hepatic hemangioma, and to provide a basis for selection of surgical procedure in clinical practice.Methods A retrospective analysis was performed for the clinical data of 115 patients who underwent surgical treatment in The Affiliated Hospital of Xuzhou Medical University from January 2010 to May2016.According to the surgical procedure, these patients were divided into peeling group (79 patients) and hepatectomy group (36 patients) .According to the tumor diameter, the patients were further divided into two subgroups for stratified comparison:89 patients with hepatic hemangioma who had a tumor diameter of 5-10 cm were divided into large peeling group with 64 patients and large hepatectomy group with 25 patients; 26 patients with a tumor diameter of >10 cm were divided into giant hemangioma peeling group with 15 patients and giant hemangioma hepatectomy group with 11 patients.The preoperative, intraoperative, and postoperative clinical data were compared between groups.The two-independent-samples t test was used for comparison of normally distributed continuous data, and the Mann-Whitney U test was used for comparison of non-normally distributed data between groups.The chi-square test and Fisher' s exact test were used for comparison of categorical data between groups.Results There were no significant differences between the hepatectomy group and the peeling group in intraoperative blood loss [300 (200-400) ml vs 300 (225-500) ml, Z=-1.065, P=0.287 ], time of operation [120 (105-160) min vs 140 (95-150) min, Z =-0.036, P = 0.971], postoperative drainage volume [280 (165-520) ml vs 310 (105-546) ml, Z=0.413, P=0.679], length of hospital stay [16 (14-19) d vs 14 (13-19.5) d, Z=-1.283, P=0.200], and hospital costs (27 973.64 ± 10 028.32 RMB vs 28 680.85 ± 10 662.87 RMB, Z=-0.344, P=0.732) .The subgroup analysis showed that there were also no significant differences between the hepatectomy group and the peeling group in intraoperative blood loss, time of operation, postoperative drainage volume, length of hospital stay, and hospital costs (all P>0.05) .Conclusion Hepatectomy and hemangioma peeling have similar clinical effects in the treatment of hepatic hemangioma.
- liver neoplasms,
- hemangioma,
- hepatectomy,
- enucleation

FullText(HTML)

References(21)

References

[1]TORO A, MAHFOUZ AE, ARDIRI A, et al.What is changing in indications and treatment of hepatic hemangiomas.A review[J].Ann Hepatol, 2014, 13 (4) :327-339.

[2]ZOU H, MA KS.Current situation on radiofrequency ablation of hepatic hemangioma[J].J Clin Hepatol, 2013, 29 (8) :567-569. (in Chinese) 邹华, 马宽生.射频消融治疗肝血管瘤的现状[J].临床肝胆病杂志, 2013, 29 (8) :567-569.

[3]GIULIANTE F, ARDITO F, VELLONE M, et al.Reappraisal of surgical indications and approach for liver hemangioma:singlecenter experience on 74 patients[J].Am J Surg, 2011, 201 (6) :741-748.

[4]DONATI M, STAVROU GA, DONATI A, et al.The risk of spontaneous rupuure of liver hemangioma:a critical review of the literature[J].J Gastrointest Surg, 2011, 15 (1) :209-214.

[5]GAO J, SUN WB.Modern views on surgical treatment of hepatic hemangioma[J].Chin J Med, 2014, 49 (12) :13-15. (in Chinese) 高君, 孙文兵.肝血管瘤外科治疗的现代观[J].中国医刊, 2014, 49 (12) :13-15.

[6]WU ZB, HUANG ZY.Indications and methods for surgical treatment of hepatic hemangioma[J].J Clin Surg, 2014, 22 (8) :616-618. (in Chinese) 吴珍宝, 黄志勇.肝血管瘤外科治疗的指征与方法[J].临床外科杂志, 2014, 22 (8) :616-618.

[7]SCHNELLDORFER T, WARE AL, SMOOT R, et al.Management of giant hemangioma of the liver:resection versus observation[J].J Am Coll Surg, 2010, 211 (6) :724-730.

[8]YEDIBELA S, ALIBEK S, MULLER V, et al.Management of hemangioma of the liver:surgical therapy on observation?[J].World J Surg, 2013, 37 (6) :1303-1312.

[9]WAGN KY, FU HQ.Surgical treatment and operative indication of hepatic hemangioma[J].Chin J Hepatobiliary Surg, 2011, 17 (9) :701-702. (in Chinese) 王开阳, 傅华群.肝血管瘤的外科治疗现状及手术指征[J].中华肝胆外科杂志, 2011, 17 (9) :701-702.

[10]DONG J, ZHU Y, WANG WL, et al.Hepatic hemangoma treated by surgical resection:a analysis of 128 patients[J].Chin J Hepatobiliary Surg, 2014, 20 (8) :595-598. (in Chinese) 董建, 朱迎, 王万里, 等.肝血管瘤128例外科治疗分析[J].中华肝胆外科杂志, 2014, 20 (8) :595-598.

[11]LERNER SM, HIATT JR, SALAMANDRA J, et al.Giant cavernous liver hemangiomas:effect of operative approach on outcome[J].Arch Surg, 2004, 139 (8) :818-821, 821-823.

[12]CHENG JJ, MA JL.Treatment progress in adult hepatic cavernous hemangioma[J].Med Recapitulate, 2013, 19 (11) :2020-2022. (in Chinese) 程炯炯, 马金良.成人肝海绵状血管瘤的治疗进展[J].医学综述, 2013, 19 (11) :2020-2022.

[13]DOU KF, JIN C.Prowess in surgery for hemangioma of liver[J].Chin J Dig Surg, 2013, 12 (1) :13-15. (in Chinese) 窦科峰, 金成.肝血管瘤外科治疗进展[J].中华消化外科杂志, 2013, 12 (1) :13-15.

[14]ZHOU CM, ZHANG JH, REN WX, et al.Treatment and clinical grading system of liver hemangioma among 514 patients[J].Chin J Dig Surg, 2015, 14 (2) :102-105. (in Chinese) 周成明, 张金辉, 任伟新, 等.514例肝血管瘤的治疗与临床评分[J].中华消化外科杂志, 2015, 14 (2) :102-105.

[15]ZHU Q, QIAO GL, YAN JJ, et al.New perspectives on the natural history and growth pattern of hepatic hemangioma in adults:a cohort study[J].Chin J Hepatobiliary Surg, 2015, 21 (11) :721-725. (in Chinese) 朱倩, 乔国梁, 晏建军, 等.对成人肝血管瘤自然发展进程及生长方式的新认识:队列研究[J].中华肝胆外科杂志, 2015, 21 (11) :721-725.

[16]GENG XP.Hepatic hemangioma and precise surgical treatment[J].Chin J Bases Clin Gen Surg, 2016, 23 (2) :137-139. (in Chinese) 耿小平.肝血管瘤与精准外科治疗[J].中国普外基础与临床杂志, 2016, 23 (2) :137-139.

[17]QIU MQ.Comparison of curative effect by resection of hepatic hemangioma and traditional operation of stripping[J].China Med Herald, 2014, 11 (19) :65-68. (in Chinese) 邱明权.肝血管瘤传统手术切除和剥离术疗效对比[J].中国医药导报, 2014, 11 (19) :65-68.

[18]MUAMMADCUMA DX, WEN H.Advances in surgical diagnosis and treatment of hepatic hemangioma[J].Xinjiang Med J, 2011, 41 (1) :91-95. (in Chinese) 买买提居马·对先, 温浩.肝血管瘤外科诊治进展[J].新疆医学, 2011, 41 (1) :91-95.

[19]QIN XL, XU J, DI WD, et al.Laparoscopic treatment of hepatic hemangioma on the operation method and curative effect of comparative analysis[J/CD].Chin J Laparoscopic Surgery:Electronic Edition, 2014, 7 (5) :350-353. (in Chinese) 秦学良, 徐钧, 底卫东, 等.腹腔镜治疗肝血管瘤手术方式选择及疗效的比较分析[J/CD].中华腔镜外科杂志:电子版, 2014, 7 (5) :350-353.

[20]WU X, XIA H, WU J, et al.Clinical experience in treatment of complex intrahepatic bile duct stones by regular hepatectomy[J].J Clin Hepatol, 2016, 32 (9) :1756-1759. (in Chinese) 吴晓, 夏灏, 吴健, 等.规则肝切除术治疗复杂肝内胆管结石的临床体会[J].临床肝胆病杂志, 2016, 32 (9) :1756-1759.

[21]LI LH, WANG JW, LIU B, et al.Clinical application of three-dimensional reconstruction in preoperative evaluation of hepatectomy[J].J Clin Hepatol, 2016, 32 (5) :938-941. (in Chinese) 李连海, 王建伟, 刘斌, 等.三维重建在肝切除术前评估中的临床应用效果[J].临床肝胆病杂志, 2016, 32 (5) :938-941.

Relative Articles

[1]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[2]	Lu Qian, Zhu Li, Cheng Xin, Huang Hua, Chen Zhong. Expression of proteasome subunit beta type 4 in hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 372-376. doi: 10.3969/j.issn.1001-5256.2020.02.028
[3]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[4]	Ye YingJian, Liu Bo, Chen Wei, Li QiongXia. Prognosis and staging system analysis of hepatocellular carcinoma patients with negative serum alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2019, 35(3): 535-541. doi: 10.3969/j.issn.1001-5256.2019.03.017
[5]	Zang YouYa, Long PeiYun, Han ZhiWei, Wang Huan, Ruan JingSheng, Huang Shan, Wu GuoBin, Chen Chuang. Establishment and verification of a nomogram for predicting patient prognosis after hepatectomy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(10): 2225-2230. doi: 10.3969/j.issn.1001-5256.2019.10.019
[6]	Chen Chuang, Long PeiYun, Chen Jie, Wang Pan, Huang QingYun, Zang YouYa, Deng GuoYu, Lin DongYi, Wang ZongYu. Value of Barcelona Clinic Liver Cancer staging system versus Hong Kong Liver Cancer staging system in predicting the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(3): 530-534. doi: 10.3969/j.issn.1001-5256.2019.03.016
[7]	Tang Ling, Qiu LuDie, Qin Wen, Wu Gang. Expression of circular RNA FLI1 in patients with hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2019.09.019
[8]	Luo Hao, Huang Jun. Clinical value of albumin-bilirubin grade in evaluating the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1608-1612. doi: 10.3969/j.issn.1001-5256.2019.07.040
[9]	He YaJing, Zhang ZhiMing, He WeiMeng, Hou JinLin. Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1302 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1002-1007. doi: 10.3969/j.issn.1001-5256.2019.05.014
[10]	Zhu Feng, Feng XiaoHai, An Yue. Association between the expression of somatostatin receptors and pathological features, prognosis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(2): 314-320. doi: 10.3969/j.issn.1001-5256.2018.02.019
[11]	Yang GuiMin, Zhao YunSheng, Wang ChunHua, Jin Liang. Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 199-203. doi: 10.3969/j.issn.1001-5256.2018.01.044
[12]	Xia DongDong, Wang EnXin, Wang WenJun, Bai Wei, Yuan Jie, Han GuoHong. Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2017, 33(6): 1120-1125. doi: 10.3969/j.issn.1001-5256.2017.06.021
[13]	Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 80-83. doi: 10.3969/j.issn.1001-5256.2016.01.013
[14]	Wang XianBo, Gao FangYuan, Liu Yao. Neutrophil- lymphocyte ratio: a novel predictor of clinical outcome of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 649-652. doi: 10.3969/j.issn.1001-5256.2016.04.007
[15]	Yang XiaoXiao, Ma Hong. Research advances in tumor markers of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 811-815. doi: 10.3969/j.issn.1001-5256.2016.04.047
[16]	Li Peng, Zhai Yun, Zhang ShiBin, Li Lei, Ding HuiGuo. Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 721-724. doi: 10.3969/j.issn.1001-5256.2015.05.021
[17]	Wang JianGang, Li HuaCheng, Fei XinYing. Application of metabolomics in research on biomarkers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(8): 836-838. doi: 10.3969/j.issn.1001-5256.2014.08.039
[18]	Jia Jia, Qi XingShun, Han GuoHong. Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(8): 576-580. doi: 10.3969/j.issn.1001-5256.2013.08.006
[19]	Zhang LiJun, Jia XiaoFang, Teng ZhenLin, Cheng NengNeng. Biomarkers of liver cancer related to hepatitis B virus selected by proteomics[J]. Journal of Clinical Hepatology, 2011, 27(5): 553-557.
[20]	Ren YiBin, Wang HongYang. The progress of diagnostic marker in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2010, 26(4): 358-360+364.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	顾智文. 射频消融术联合奥沙利铂加卡培他滨方案用于结直肠癌术后肝转移患者的临床价值. 大医生. 2024(01): 25-28 .
2.	刘炫鳞，买佳琪，马文兵. 脾多肽注射液联合西妥昔、mFOLFOX6方案对直肠癌肝转移患者生存质量及TRF1、TRF2表达的影响. 临床医学研究与实践. 2023(25): 29-32 .
3.	林守英，周庄，刘丽雅. 薏苡附子败酱散联合XELOX方案对结直肠癌患者免疫功能、肠道菌群的影响. 实用中西医结合临床. 2023(21): 37-40 .
4.	张洋，杨帆，王景景. 沙利度胺联合XELOX方案化疗治疗转移性结直肠癌的疗效及对生存率的影响. 癌症进展. 2022(07): 727-730 .
5.	苏华冠，谢礼福，刘奕武，赖光芒. 腹腔镜下结直肠癌切除术联合肝转移瘤射频消融术治疗结直肠癌肝转移. 中国肝脏病杂志(电子版). 2021(02): 13-18 .
6.	王强. 经皮肝射频消融术联合经导管肝动脉灌注化疗治疗晚期结直肠癌多发肝转移瘤患者的效果. 中国民康医学. 2021(23): 19-22 .
7.	刘信，刘放，刘也夫，谢峰，张睿. 术中开腹彩超引导下射频与经皮CT引导射频治疗结直肠癌肝转移疗效比较研究. 临床军医杂志. 2020(02): 167-169 .
8.	高岩，蓝宇，贾纯增. 内镜黏膜下剥离术治疗早期结直肠癌及癌前病变临床效果观察. 临床军医杂志. 2020(06): 668-671+675 .
9.	吕厚宽，庄文辉，刘晓晖，郭泽才，刘琪. 卡培他滨联合奥沙利铂治疗直肠癌的临床疗效研究. 长春中医药大学学报. 2020(04): 741-744 .
10.	李江，候宇，蔡晓蓓，徐承雷，易根发. 基于限制性肝段切除手术的局部治疗模式改善结直肠癌术后肝脏寡转移的预后分析. 临床肝胆病杂志. 2020(08): 1763-1767 . 本站查看
11.	彭文杰. AFP、CCL2和HP在结直肠癌肝转移诊断中的临床应用研究. 国际生物医学工程杂志. 2019(05): 414-418 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2529) PDF downloads(419)

Clinical effect of hepatectomy versus extracapsular peeling in treatment of hepatic hemangioma

DOI: 10.3969/j.issn.1001-5256.2017.04.020